Seo Eun Hyun, Kim Seung-Gon, Lee Jae-Hon, Yoon Hyung-Jun
Premedical Science, College of Medicine, Chosun University, Gwangju, Korea.
Department of Psychiatry, College of Medicine, Chosun University, Gwangju, Korea.
Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):604-608. doi: 10.9758/cpn.22.1044.
Lamotrigine and aripiprazole have shown efficacy as augmentation agents of serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder (OCD). To date, the efficacy of lamotrigine/aripiprazole augmentation has not been reported in OCD treatment. Herein, we report the case of a 37-year-old male with severe OCD and comorbid depression whose symptoms markedly improved after low-dose lamotrigine/aripiprazole augmentation to clomipramine. Our report suggests that early glutamatergic/antipsychotic augmentation contributes to rapid remission of OCD symptoms.
拉莫三嗪和阿立哌唑已显示出作为5-羟色胺再摄取抑制剂的增效剂用于治疗难治性强迫症(OCD)的疗效。迄今为止,拉莫三嗪/阿立哌唑增效在强迫症治疗中的疗效尚未见报道。在此,我们报告一例37岁患有重度强迫症并伴有共病性抑郁症的男性患者,在氯米帕明基础上加用低剂量拉莫三嗪/阿立哌唑后症状显著改善。我们的报告表明,早期谷氨酸能/抗精神病药物增效有助于强迫症症状的快速缓解。